WHO 1st time approved Biosimilar of “Trastuzumab” for breast cancer treatment

The World Health Organization (WHO) announced that for the 1st time it had approved a “biosimilar” medicine of Trastuzumab named “Ontruzant” to make cheaper breast cancer treatment at an affordable rate to women globally. The medicine is derived from living sources rather than chemicals. The biosimilar medicine of the Trastuzumab drug was supplied by Samsung Bioepis co Ltd.

Important takeaways for all competitive exams:

  • WHO Headquarters: Geneva, Switzerland, Director general: Tedros Adhanom.

Source: The WHO

Find More Sci-Tech News Here